Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
about
Effects of the blood coagulation vitamin K as an inhibitor of arterial calcificationOsteoprotegerin (OPG) as a biomarker for diabetic cardiovascular complications.Potassium channel-blockers as therapeutic agents to interfere with bone resorption of periodontal diseaseLocal application of osteoprotegerin-chitosan gel in critical-sized defects in a rabbit modelOsteoprotegerin as a marker of atherosclerosis: a systematic update.Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.Death receptors and their role in dermatology, with particular focus on tumor necrosis factor-related apoptosis-inducing ligand receptors.Immunoregulation of bone remodellingPlasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.Nonsteroid immune modulators and bone disease.Effect of kidney transplantation on bone.Association of serum osteoprotegerin with vascular calcification in patients with type 2 diabetes.The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease.Bone metabolism and vascular calcification.Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.Osteoprotegerin is an independent predictor of vascular events in Finnish adults with type 1 diabetesOsteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.Osteoprotegerin, vascular calcification and atherosclerosis.Optimization of Bone Health in Children before and after Renal Transplantation: Current Perspectives and Future Directions.The role of osteoprotegerin in cardiovascular disease.Can bone loss in rheumatoid arthritis be prevented?Evaluation of the effects of two different bone resorption inhibitors on osteoclast numbers and activity: An animal study.Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus.Markers of bone remodeling are associated with arterial stiffness in renal transplanted subjects.TNFRSF11B polymorphisms are associated with metabolic traits in Uyghur and Han ethnic groups.Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction.Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis.Association of plasma osteoprotegerin levels with stroke severity and functional outcome in acute ischaemic stroke patients.The role of serum osteoprotegerin and S-100 protein levels in patients with acute ischaemic stroke: determination of stroke subtype, severity and mortality.Circulating osteoprotegerin is correlated with lipid profile, insulin sensitivity, adiponectin and sex steroids in an ageing male population.Periostin and receptor activator of nuclear factor κ-B ligand expression in allergic fungal rhinosinusitis.High osteoprotegerin levels predict MACCE in STEMI patients, but are not associated with myocardial salvage.Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis.The Role of Osteoprotegerin as a Cardioprotective Versus Reactive Inflammatory Marker: the Chicken or the Egg ParadoxmTORC1 impedes osteoclast differentiation via calcineurin and NFATc1Osteoprotegerin independently predicts mortality in patients with stable coronary artery disease: The CLARICOR trialOsteoprotegerin and Cardiovascular Events in High-Risk Populations: Meta-Analysis of 19 Prospective Studies Involving 27 450 Participants
P2860
Q24654794-2648398E-5F78-4706-9847-D22FBBFF78DCQ27692635-280D6CE8-F52F-4207-A9D0-F9A06E5A4767Q28252713-36FA35CB-5681-4565-9661-64E4A660A855Q33862655-6376670F-00CC-4C93-ABB1-9269EFB5281BQ34234163-B74F74C4-31FA-4F57-AF01-5098F4601EA6Q34399438-D7B44337-3A66-416B-81D7-77B49D923D84Q35064380-A0E2BDDE-88F4-4B9B-B1AA-A138FF4E42F2Q36107934-0F0A8AFE-3028-41A9-B7AE-4B609E2F4FDFQ36388215-D571FCFA-3C3B-43D3-B1CE-156A053779B3Q36532542-8BAE98A1-7970-405D-A568-ACD2CBCB8F78Q36554790-74890999-E988-4E11-AF1D-AE8829378B7EQ36571983-B65B4736-1D3C-4376-A5BC-07EDBE3658BFQ36686037-84F5CB1B-563B-4EDD-B19A-276C4FDC08E5Q36777391-25C949CE-B508-4F09-A901-80B2EDD4B44FQ36860987-071892D1-5777-4B63-8BEF-FADC1CC98BE8Q36942172-20907E58-980D-49E3-B8DE-6788F27EBF62Q37188485-E17F86F4-8699-431A-9F43-1F94C934B863Q37310825-09BD6159-E14B-440D-9154-6DF37430EC9AQ37598894-59026129-77A9-4F52-AD1A-162C44D714AEQ38056541-43346B59-40AF-48F5-B3ED-A0DD6CDA1952Q38115190-6BCCEF4C-5F6B-442D-8D47-FAACFB478B1EQ38969971-64E0E44A-FA8A-4438-A044-B117494EFA8EQ40396910-64EAFEE3-0FDF-4D9A-AE57-84FE479BAC4AQ41003926-9957408F-E22D-404F-9EB8-32DCBC9A77DDQ44037048-20B068AB-47B0-4235-9A83-0D1F51A7D4D7Q45057604-528C63E0-A2DC-438E-9451-63EF70CEE21FQ46535196-D1991512-136E-4792-B3FD-888F20A5F005Q48353042-0F2CC834-7BFF-4BA3-9685-A440586ED6EBQ48961249-46DA67D1-DB17-42CA-B480-A1EB4A250252Q51497817-638C681E-C8F9-4800-9D77-29A829C50A57Q53058911-6FC9CD03-9A7C-4103-B8D0-875E6E236B8FQ53068399-62028627-5662-4643-BDE2-26E652AA6077Q54518432-3A103949-CAF7-4EDC-8696-E606D2E96D0CQ55285084-770E7450-59DF-4FEF-9026-EBC815C34779Q57146434-C2DDB7D9-4143-4B7D-AA2A-990FA3849FA9Q57389466-831F7B4A-A817-4019-AB47-CCA6BA0F7195Q58129712-09F1CA81-CE8E-4DE3-86C9-3C81D80DD811
P2860
Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Effects of immunosuppressants ...... ry artery smooth muscle cells.
@ast
Effects of immunosuppressants ...... ry artery smooth muscle cells.
@en
type
label
Effects of immunosuppressants ...... ry artery smooth muscle cells.
@ast
Effects of immunosuppressants ...... ry artery smooth muscle cells.
@en
prefLabel
Effects of immunosuppressants ...... ry artery smooth muscle cells.
@ast
Effects of immunosuppressants ...... ry artery smooth muscle cells.
@en
P2093
P356
P1476
Effects of immunosuppressants ...... ry artery smooth muscle cells.
@en
P2093
Dunstan CR
Hofbauer LC
Spelsberg TC
P304
P356
10.1006/BBRC.2000.4130
P407
P577
2001-01-01T00:00:00Z